VYNE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VYNE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.
VYNE Therapeutics's annual accumulated depreciation declined from Dec. 2021 ($-0.55 Mil) to Dec. 2022 ($0.00 Mil) but then stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).
The historical data trend for VYNE Therapeutics's Accumulated Depreciation can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VYNE Therapeutics Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Accumulated Depreciation | Get a 7-Day Free Trial | - | -0.44 | -0.55 | - | - |
VYNE Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Accumulated Depreciation | Get a 7-Day Free Trial | - | - | - | - | - |
The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.
Thank you for viewing the detailed overview of VYNE Therapeutics's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.
Patrick G Lepore | director | 17-17 ROUTE 208 N, FAIRLAWN NJ 07410 |
Mutya Harsch | officer: Chief Legal Officer and GC | C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Tyler Zeronda | officer: Interim CFO | C/O VYNE THERAPEUTICS, 520 U.S. HIGHWAY 22, SUITE 204, BRIDGEWATER NJ 08807 |
Andrew Saik | officer: Chief Financial Officer | 640 LEE ROAD, CHESTERBROOK PA 19087 |
Rex Bright | director | 5641 LAKE VISTA DRIVE, BONSALL CA 92003 |
Iain Stuart | officer: Chief Scientific Officer | C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704 |
David Domzalski | director, officer: President and CEO | C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704 |
Matthew T. Wiley | officer: Chief Commercial Officer | C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLTZMAN ST, WEIZMANN SCIENCE PARK, REHOVOT L3 7670402 |
Anthony D Bruno | director | C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866 |
Stanley Hirsch | director | C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704 |
Ilan Hadar | officer: CFO and Country Manager | C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704 |
Sharon Surrey Barbari | director | 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Perceptive Advisors Llc | 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Joseph Edelman | director, 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
From GuruFocus
By Marketwired • 07-09-2024
By sperokesalga sperokesalga • 02-28-2023
By GuruFocus Research • 11-14-2023
By sperokesalga sperokesalga • 05-18-2023
By Value_Insider Value_Insider • 12-07-2022
By sperokesalga sperokesalga • 02-10-2023
By Marketwired • 11-01-2023
By Marketwired • 09-06-2023
By Marketwired • 08-14-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.